Last reviewed · How we verify

Fluticasone propionate/salmeterol Inhalation Powder

GlaxoSmithKline · Phase 3 active Small molecule

Fluticasone propionate/salmeterol Inhalation Powder is a Inhaled corticosteroid/long-acting beta-2 agonist combination Small molecule drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.

Fluticasone propionate (a corticosteroid) reduces airway inflammation while salmeterol (a long-acting beta-2 agonist) relaxes airway smooth muscle to improve breathing.

Fluticasone propionate (a corticosteroid) reduces airway inflammation while salmeterol (a long-acting beta-2 agonist) relaxes airway smooth muscle to improve breathing. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.

At a glance

Generic nameFluticasone propionate/salmeterol Inhalation Powder
SponsorGlaxoSmithKline
Drug classInhaled corticosteroid/long-acting beta-2 agonist combination
TargetGlucocorticoid receptor; beta-2 adrenergic receptor
ModalitySmall molecule
Therapeutic areaRespiratory/Pulmonology
PhasePhase 3

Mechanism of action

Fluticasone propionate binds to glucocorticoid receptors in the lungs, suppressing inflammatory cytokine production and reducing airway edema and mucus secretion. Salmeterol activates beta-2 adrenergic receptors on airway smooth muscle, causing bronchodilation and sustained airway opening. Together, they provide both anti-inflammatory and bronchodilator effects for maintenance therapy.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Fluticasone propionate/salmeterol Inhalation Powder

What is Fluticasone propionate/salmeterol Inhalation Powder?

Fluticasone propionate/salmeterol Inhalation Powder is a Inhaled corticosteroid/long-acting beta-2 agonist combination drug developed by GlaxoSmithKline, indicated for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.

How does Fluticasone propionate/salmeterol Inhalation Powder work?

Fluticasone propionate (a corticosteroid) reduces airway inflammation while salmeterol (a long-acting beta-2 agonist) relaxes airway smooth muscle to improve breathing.

What is Fluticasone propionate/salmeterol Inhalation Powder used for?

Fluticasone propionate/salmeterol Inhalation Powder is indicated for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.

Who makes Fluticasone propionate/salmeterol Inhalation Powder?

Fluticasone propionate/salmeterol Inhalation Powder is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).

What drug class is Fluticasone propionate/salmeterol Inhalation Powder in?

Fluticasone propionate/salmeterol Inhalation Powder belongs to the Inhaled corticosteroid/long-acting beta-2 agonist combination class. See all Inhaled corticosteroid/long-acting beta-2 agonist combination drugs at /class/inhaled-corticosteroid-long-acting-beta-2-agonist-combination.

What development phase is Fluticasone propionate/salmeterol Inhalation Powder in?

Fluticasone propionate/salmeterol Inhalation Powder is in Phase 3.

What are the side effects of Fluticasone propionate/salmeterol Inhalation Powder?

Common side effects of Fluticasone propionate/salmeterol Inhalation Powder include Tremor, Headache, Nervousness/anxiety, Oral candidiasis, Hoarseness, Palpitations.

What does Fluticasone propionate/salmeterol Inhalation Powder target?

Fluticasone propionate/salmeterol Inhalation Powder targets Glucocorticoid receptor; beta-2 adrenergic receptor and is a Inhaled corticosteroid/long-acting beta-2 agonist combination.

Related